GlassScriptPhysician profile
Nezam H Afdhal
NPI 1508973173
$331,504.83
in general payments reported to CMS, 2019-2025
10 companies · $60K in 2025
The $60K reported for 2025 was more than what 87% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96K · 2020: $45K · 2021: $25K · 2022: $4,000 · 2023: $28K · 2024: $74K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $161K · Travel and Lodging: $646 · Food and Beverage: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $161,433.93 |
| Travel and Lodging | $646.06 |
| Food and Beverage | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $126,666.00 | 2023-2025 | |
| Gilead Sciences, INC. | $118,405.24 | 2019-2023 | |
| Glaxosmithkline, LLC. | $39,437.43 | 2020-2024 | |
| Shionogi INC | $17,095.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $14,640.00 | 2025 | |
| Echosens North America, INC. | $10,500.00 | 2019-2021 | |
| Novo Nordisk INC | $2,712.50 | 2023 | |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Madrigal Pharmaceuticals | $48.00 | 2024 | Resmetirom |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nezam Afdhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.